CVS Stock Analysis: Buy, Sell, or Hold?
CVS - CVS HEALTH CORPORATION
$105.90
1.75 (1.68%)
▲
5d:
+3.74%
30d:
+8.04%
90d:
+33.49%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 6.6/10
Get Alerted When CVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called CVS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CVS trades at premium valuation expecting 6.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CVS trades at premium valuation expecting 6.1% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$133.60
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$82.95
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CVS is currently trading at $105.90, which is considered extended relative to its 30-day fair value range of $98.45 to $104.50. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.6) compared to its historical average (10.6). At these levels, the market is pricing in 6.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CVS is in a strong uptrend. The price is approaching resistance at $102.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CVS is in a strong uptrend. The price is approaching resistance at $102.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$98.45 -
$104.50
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
45.2%
Protect Your Profits
Holding CVS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($108.81)
- NEUTRAL: Trading at premium valuation - market expects 6.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$98.45 -
$104.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$89.42
Resistance Level
$102.77
Current Trend
Strong Uptrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.61
Wall Street Target
$108.81
(+2.7%)
Revenue Growth (YoY)
6.1%
Earnings Growth (YoY)
63.1%
Profit Margin
0.7%
Valuation Premium vs History
+6.1% premium
PE vs Historical
12.6 vs 10.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.1%
(market-implied from PE analysis)
1-Year Target
$112.36
(+6%)
2-Year Target
$119.21
(+13%)
3-Year Target
$126.49
(+19%)
3-Yr Target (if PE normalizes)
(PE: 13→11)
PE COMPRESSION
$106.35
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 13.0%)
$263.98
(+149%)
Base:
(SPY PE: 12.6, Growth: 13.0%)
$152.80
(+44%)
Bear:
(PE: 10.6, Growth: 13.0%)
$128.48
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 45.68 | Current EPS (TTM): $2.28
Bull Case
$229.13
(+116%)
Analyst growth 100.0%, PE expands to 50.3
Base Case
$208.30
(+97%)
Market implied 100.0%, PE stable at 45.7
Bear Case
$70.82
(-33%)
Severe decline -20.0%, PE contracts to 38.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 6:22 PM ET
Data refreshes hourly during market hours. Next update: 7:22 PM
Data refreshes hourly during market hours. Next update: 7:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVS showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna
SELL
2026-02-24
Michael T. McCaul
BUY
2026-02-20
John Boozman
BUY
2026-01-29
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$420 | 54 HOLD |
|
CI
Cigna Corp |
STRONG BUY
25 analysts |
$341 | 62 BUY |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$431 | 64 BUY |
|
HUM
Humana Inc |
HOLD
26 analysts |
$315 | 58 HOLD |
|
CNC
Centene Corp |
BUY
19 analysts |
$63 | 56 HOLD |
Advanced CVS Option Strategies
Professional options setups generated by AI based on today's CVS price and gamma walls.
